Cargando…

Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study

BACKGROUND: Today, the treatment of choice for high- and low-grade gliomas requires primarily surgical resection to achieve the best survival and quality of life. Nevertheless, many gliomas within highly eloquent cortical regions, e.g., insula, rolandic, and left perisylvian cortex, still do not und...

Descripción completa

Detalles Bibliográficos
Autores principales: Krieg, Sandro M, Schnurbus, Lea, Shiban, Ehab, Droese, Doris, Obermueller, Thomas, Buchmann, Niels, Gempt, Jens, Meyer, Bernhard, Ringel, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583679/
https://www.ncbi.nlm.nih.gov/pubmed/23374675
http://dx.doi.org/10.1186/1471-2407-13-51
_version_ 1782475462962839552
author Krieg, Sandro M
Schnurbus, Lea
Shiban, Ehab
Droese, Doris
Obermueller, Thomas
Buchmann, Niels
Gempt, Jens
Meyer, Bernhard
Ringel, Florian
author_facet Krieg, Sandro M
Schnurbus, Lea
Shiban, Ehab
Droese, Doris
Obermueller, Thomas
Buchmann, Niels
Gempt, Jens
Meyer, Bernhard
Ringel, Florian
author_sort Krieg, Sandro M
collection PubMed
description BACKGROUND: Today, the treatment of choice for high- and low-grade gliomas requires primarily surgical resection to achieve the best survival and quality of life. Nevertheless, many gliomas within highly eloquent cortical regions, e.g., insula, rolandic, and left perisylvian cortex, still do not undergo surgery because of the impending risk of surgery-related deficits at some centers. However, pre and intraoperative brain mapping, intraoperative neuromonitoring (IOM), and awake surgery increase safety, which allows resection of most of these tumors with a considerably low rate of postoperatively new deficits. METHODS: Between 2006 and 2012, we resected 47 out of 51 supratentorial gliomas (92%), which were primarily evaluated to be non-resectable during previous presentation at another neurosurgical department. Out of these, 25 were glioblastomas WHO grade IV (53%), 14 were anaplastic astrocytomas WHO grade III (30%), 7 were diffuse astrocytomas WHO grade II (15%), and one was a pilocytic astrocytoma WHO grade I (2%). All data, including pre and intraoperative brain mapping and monitoring (IOM) by motor evoked potentials (MEPs) were reviewed and related to the postoperative outcome. RESULTS: Awake surgery was performed in 8 cases (17%). IOM was required in 38 cases (81%) and was stable in 18 cases (47%), whereas MEPs changed the surgical strategy in 10 cases (26%). Thereby, gross total resection was achieved in 35 cases (74%). Postoperatively, 17 of 47 patients (36%) had a new motor or language deficit, which remained permanent in 8.5% (4 patients). Progression-free follow-up was 11.3 months (range: 2 weeks – 64.5 months) and median survival was 14.8 months (range: 4 weeks – 20.5 months). Median Karnofsky Performance Scale was 85 before and 80 after surgery). CONCLUSIONS: In specialized centers, most highly eloquent gliomas are eligible for surgical resection with an acceptable rate of surgery-related deficits; therefore, they should be referred to specialized centers.
format Online
Article
Text
id pubmed-3583679
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35836792013-02-28 Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study Krieg, Sandro M Schnurbus, Lea Shiban, Ehab Droese, Doris Obermueller, Thomas Buchmann, Niels Gempt, Jens Meyer, Bernhard Ringel, Florian BMC Cancer Research Article BACKGROUND: Today, the treatment of choice for high- and low-grade gliomas requires primarily surgical resection to achieve the best survival and quality of life. Nevertheless, many gliomas within highly eloquent cortical regions, e.g., insula, rolandic, and left perisylvian cortex, still do not undergo surgery because of the impending risk of surgery-related deficits at some centers. However, pre and intraoperative brain mapping, intraoperative neuromonitoring (IOM), and awake surgery increase safety, which allows resection of most of these tumors with a considerably low rate of postoperatively new deficits. METHODS: Between 2006 and 2012, we resected 47 out of 51 supratentorial gliomas (92%), which were primarily evaluated to be non-resectable during previous presentation at another neurosurgical department. Out of these, 25 were glioblastomas WHO grade IV (53%), 14 were anaplastic astrocytomas WHO grade III (30%), 7 were diffuse astrocytomas WHO grade II (15%), and one was a pilocytic astrocytoma WHO grade I (2%). All data, including pre and intraoperative brain mapping and monitoring (IOM) by motor evoked potentials (MEPs) were reviewed and related to the postoperative outcome. RESULTS: Awake surgery was performed in 8 cases (17%). IOM was required in 38 cases (81%) and was stable in 18 cases (47%), whereas MEPs changed the surgical strategy in 10 cases (26%). Thereby, gross total resection was achieved in 35 cases (74%). Postoperatively, 17 of 47 patients (36%) had a new motor or language deficit, which remained permanent in 8.5% (4 patients). Progression-free follow-up was 11.3 months (range: 2 weeks – 64.5 months) and median survival was 14.8 months (range: 4 weeks – 20.5 months). Median Karnofsky Performance Scale was 85 before and 80 after surgery). CONCLUSIONS: In specialized centers, most highly eloquent gliomas are eligible for surgical resection with an acceptable rate of surgery-related deficits; therefore, they should be referred to specialized centers. BioMed Central 2013-02-02 /pmc/articles/PMC3583679/ /pubmed/23374675 http://dx.doi.org/10.1186/1471-2407-13-51 Text en Copyright ©2013 Krieg et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Krieg, Sandro M
Schnurbus, Lea
Shiban, Ehab
Droese, Doris
Obermueller, Thomas
Buchmann, Niels
Gempt, Jens
Meyer, Bernhard
Ringel, Florian
Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study
title Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study
title_full Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study
title_fullStr Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study
title_full_unstemmed Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study
title_short Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study
title_sort surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583679/
https://www.ncbi.nlm.nih.gov/pubmed/23374675
http://dx.doi.org/10.1186/1471-2407-13-51
work_keys_str_mv AT kriegsandrom surgeryofhighlyeloquentgliomasprimarilyassessedasnonresectablerisksandbenefitsinacohortstudy
AT schnurbuslea surgeryofhighlyeloquentgliomasprimarilyassessedasnonresectablerisksandbenefitsinacohortstudy
AT shibanehab surgeryofhighlyeloquentgliomasprimarilyassessedasnonresectablerisksandbenefitsinacohortstudy
AT droesedoris surgeryofhighlyeloquentgliomasprimarilyassessedasnonresectablerisksandbenefitsinacohortstudy
AT obermuellerthomas surgeryofhighlyeloquentgliomasprimarilyassessedasnonresectablerisksandbenefitsinacohortstudy
AT buchmannniels surgeryofhighlyeloquentgliomasprimarilyassessedasnonresectablerisksandbenefitsinacohortstudy
AT gemptjens surgeryofhighlyeloquentgliomasprimarilyassessedasnonresectablerisksandbenefitsinacohortstudy
AT meyerbernhard surgeryofhighlyeloquentgliomasprimarilyassessedasnonresectablerisksandbenefitsinacohortstudy
AT ringelflorian surgeryofhighlyeloquentgliomasprimarilyassessedasnonresectablerisksandbenefitsinacohortstudy